Non-Hodgkin Lymphoma

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.

Low vitamin D levels prior to treatment may be linked to risk of relapse or death for patients with follicular lymphoma.

M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.

Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies.

In an interview with OncLive, Randy Gascoyne, MD, explains how predictive biomarkers can help oncologists select the right therapies for their patients and why they are the critical next step to improving outcomes in NHL.

Randy Gascoyne, MD, hematopathologist and research director for the Centre for Lymphoid Cancers at the BC Cancer Agency in Canada, discusses a study that investigated biomarkers for follicular lymphoma.

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

Ibrutinib (Imbruvica) showed promising activity in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia after allogeneic stem cell transplantation, according to data presented at the American Society for Blood and Marrow Transplantation 2015 BMT Tandem Meeting.

Are the high costs of breakthrough therapies for blood cancers, some with price tags of more than $100,000 per year, worth the improved outcomes for patients?

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.